Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.915 USD | +0.26% | +1.86% | -27.46% |
08/04 | Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024 | |
08/04 | North American Morning Briefing : Inflation Data, -2- | DJ |
Business Summary
Number of employees: 53
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Injectable Biologics
100.0
%
| 1 | 100.0 % | 5 | 100.0 % | +340.88% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 5 | 100.0 % | +340.88% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Daniel Passeri
CEO | Chief Executive Officer | 63 | 01/16/01 |
Anish Suri
PSD | President | 50 | 01/18/01 |
Kerri-Ann Millar
DFI | Director of Finance/CFO | 54 | 01/17/01 |
Matteo Levisetti
CTO | Chief Tech/Sci/R&D Officer | 55 | 22/21/22 |
Marie Campinell
IRC | Investor Relations Contact | - | - |
Colin Sandercock
LAW | General Counsel | 67 | 01/17/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 74 | 26/18/26 |
Daniel Passeri
CEO | Chief Executive Officer | 63 | 01/16/01 |
Peter Kiener
BRD | Director/Board Member | 72 | 01/16/01 |
Frank Morich
CHM | Chairman | 69 | 03/18/03 |
Patrick Verheyen
BRD | Director/Board Member | 64 | 11/23/11 |
Pamela Garzone
BRD | Director/Board Member | 69 | 19/23/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 48,643,316 | 47,197,910 ( 97.03 %) | 0 | 97.03 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.46% | 92.91M | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- CUE Stock
- Company Cue Biopharma, Inc.